If that's the case, obviously rdea can't license 806 prior to phase 2B without some sort of amended agreement with Valeant. Valeant has no rights to the gout program.
<<For the HIV program (as opposed to the gout program), this option may be moot insofar as RDEA does not plan to start a phase-2b trial without a partner.>>>
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.